// App-Quantinova.ai

: Improvements in joint health during long‐term use of recombinant factor VIII Fc fusion protein prophylaxis in subjects with haemophilia A

Researchers

Presenter

  • J. Oldenburg

Principal Investigators

  • J. Pasi

  • I. Pabinger

  • B. Nolan

  • R. Kulkarni

  • V. Blanchette

  • N. Tripkovic

  • J. Feng

  • N. Jain

Medical Centers

  • Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany

  • Barts and the London Comprehensive Care Center, London, United Kingdom

  • Medizinische Universitaet Wien, Vienna, Austria

  • Our Lady's Children's Hospital, Dublin, Ireland

  • Michigan State University, East Lansing, MI, United States

  • Hospital for Sick Children, Toronto, ON, Canada

  • Sobi, Stockholm, Sweden

  • Bioverativ, a Sanofi Company, Waltham, MA, United States

Locations

  • Germany

  • United Kingdom

  • Austria

  • Ireland

  • United States

  • Canada

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • Recombinant Factor VIII

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Bioverativ

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved